

Dear editor:

Submitted is the revised manuscript by Guan-Min Lai et al. entitled “Hepatitis B Reactivation in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor” , **ESPS Manuscript NO: 1559**, which is for publication in *Case Report* section of *World Journal of Gastroenterology*. Responses to reviewer’s comments are described point by point as follows:

1. In the Abstract section, “We report here **2 cases** of hepatitis B virus reactivation in chronic myeloid leukemia patients receiving imatinib mesylate **and a novel case** of nilotinib related Hepatitis B virus reactivation.” is described. Actually, we report 3 cases in this manuscript.
2. Results of pretreatment liver panel are added in the Case Report section. Added sentences are marked red-colored.
3. EASL guidelines recommend preemptive therapy with nucleoside/nucleotide analogues in HBsAg-positive patients undergoing immunosuppressive chemotherapy. However, TKIs (imatinib and nilotinib) are thought to be immunomodulatory, rather than immunosuppressive. There is no recommendation on whether NAs should be given in patients undergoing TKI therapy due to lack of prospective studies. We add 2 sentences in the Discussion section and are marked red-colored.
4. Immunosuppressive chemotherapy should be discontinued if HBV reactivation is encountered during chemotherapy. However, TKIs are thought to be immunomodulatory, rather than immunosuppressive. Further prospective studies are needed to decide whether TKIs should be discontinued in patients with HBV reactivation.

Furthermore, responses to editor’s comments are described as follows:

1. Language editing certificate is provided.
2. Author contribution and telephone number are changed accordingly.
3. DOI and PMID are added in the References section.
4. Figures are provided with no smaller than 85 mm in height and 126 mm in width, and at a resolution of 600 dpi as TIFF format.

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Yours Sincerely,
Guan-Min Lai
Sheng-Lei Yan,
Cheng-Shyong Chang and

Chien-Yu Tsai

Corresponding Author:

Cheng-Shyong Chang, MD

Division of Hemato-Oncology, Department of Internal Medicine, Changhua
Christian Hospital, Changhua 500, Taiwan

E-mail: 15120@cch.org.tw

Telephone: +88647238595

Fax: +8867232946